The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

NSH - BMT Program Publishes 2016 Winter Newsletter

Our 2016 Winter Newsletter lead article, ‘Inhibition of FLT-3 Following Allogeneic Transplants’, reviews NSH 1114, a phase II, randomized comparative trial of standard of care, with or without midostaurin to prevent relapse following allogeneic HSCT in patients with FLT3-ITD mutated acute myeloid leukemia. A positive FLT-3 genetic mutation is a prognostic indicator for poor survival outcome. The Newsletter also includes 2015 programmatic highlights.

Please click here to read the full version of the NSH-BMT Winter Newsletter.

Northside Hospital’s #FaceLeukemia Gives Patients Social Media Platform to Raise Community Awareness of Complex Blood Cancer

For the September 2015 Blood Cancer Awareness Month, Northside Hospital in conjunction with the NSH-Leukemia Program, launched a month-long feature following the recent journeys of four leukemia patients through their diagnosis, treatment and recovery.

Our hope is that their stories will bring awareness to the struggles they faced battling cancer and to inspire you as much as they have inspired us to support leukemia research at Northside and Northside’s leukemia programs. Please go to Leukemia for additional NSH- Leukemia Program information.

Please view NSH-Leukemia patient journeys from illness to wellness on or on social media use #faceleukemia and join us on, and

Help create more leukemia survivors

Secure online and tax deductible giving is available to help fund research, education and other patient support services for the Leukemia Program through the Northside Hospital Foundation. Call (770) 667-4483 (GIVE) or visit for more information.

NSH-Leukemia Program Featured on NBC Affiliate 11 Alive News

On October 13, 2015, NSH-Leukemia Physician, Dr. Asad Bashey, spoke to 11 Alive News about Katherine Welch, a newly diagnosed NSH - Leukemia patient, who is twenty four weeks pregnant and undergoing lifesaving chemotherapy treatment for herself and unborn child.

With access to state-of-the-art diagnostic testing, comprehensive patient-centered care, and bone marrow transplant services, the NSH- Leukemia Program provides patients with the exceptional quality care needed to treat their blood-related malignancy. Please go to Leukemia for additional information.

For the Sixth Consecutive Year, NSH-BMT's One Year Related and Unrelated Allogeneic Transplant Survival Outcomes Were Among the Best in the U.S.1,2

1. Reported outcome data from This survival information includes only patients who received their first allogeneic transplant between January 1, 2010 and December 31, 2012 using unrelated or related donors, and who had reported follow-up.
2. Final 2014 Transplant Center Specific Survival Report, November 24, 2014.

Please go to Survival for additional NSH-BMT survival outcome data information.

57th Annual American Society of Hematology (ASH) Meeting: NSH-BMT/Leukemia Programs Will Present One Oral and Eight Poster Presentations

Dr. Asad Bashey will present ‘Non-Inferior survival of black versus white patients and superior outcomes for black females compared to other race/gender groups following allogeneic transplantation for hematologic malignancy: A single center multivariable analysis of 475 allografted patients’ at the 2015 annual American Society of Hematology meeting. Eight poster presentations have also been accepted.

By participating and developing state-the-art clinical research trials, the Program continues to advance the field of blood and marrow transplant and leukemia therapies, improve survival outcomes and quality of life.

Please go to Publications to review the 2015 ASH oral and poster presentations.

NSH-BMT’s CIBMTR Scientific Working Committee Leadership Recognition

After the 2014-2015 review of the CIBMTR’s Scientific Working Committees, four have been recognized as outstanding by the Advisory Committee:

  • Chronic Leukemia
  • Graft Sources and Manipulation – NSH-BMT’s Asad Bashey, PhD, Chair
  • Late Effects and Quality of Life
  • Lymphoma

These committees were identified because of their strong promotion of studies that will have a notable impact on the field, willingness to forgo studies that will not have a significant impact on the field, and focus on the effective use of CIBMTR resources. In addition, these committees have cultivated external collaborations and are notably well-organized and highly productive.

For a full list of CIBMTR Scientific Working Committee leadership recognition, please review here.

Open to Enrollment: A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies

Click Here for Details

NSH- BMT/Leukemia Patient Craig Sager’s Message of Hope

TNT's Inside the NBA Interview

NSH-BMT Program Named as Core Clinical Transplant Center

NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.


Join the Fight Against Cancer

By donating platelets and blood you can join the fight and directly impact the healthcare of patients being treated at NSH-BMT/Leukemia by donating with Atlanta Blood Services. To donate or find out additional information please go to Or Click here to Like ABS on Facebook:


The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.